Navigation Links
Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
Date:4/21/2008

Patient Dosing Underway in Company's First Clinical Program

NOVATO, Calif., April 21 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia(TM) program. Convivia(TM) is Bennu's proprietary, oral formulation of 4-MP designed to reduce peak systemic acetaldehyde levels in ALDH2 deficient persons following alcohol consumption.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

ALDH2 deficiency, sometimes referred to as "Asian flushing syndrome," is an inherited metabolic disorder affecting 40% to 50% of East Asian populations, impairing the activity of the liver enzyme aldehyde dehydrogenase ("ALDH2"). When people with ALDH2 deficiency drink alcoholic beverages, there is an accumulation of acetaldehyde, a carcinogenic intermediate in the metabolism of ethanol, in blood and tissues. Published retrospective studies have observed a significant correlation between recurrent drinkers with ALDH2 deficiency and an increase in risk for digestive tract cancers, liver diseases, late-onset Alzheimer's disease and other serious health disorders. In addition to the long-term health risks, elevated acetaldehyde levels produce acute symptoms, including facial flushing, tachycardia (rapid heart rate), headache, nausea and dizziness.

Although ALDH2 deficient people suffer from unpleasant reactions and face long-term health risks, a substantial proportion of them are recurring drinkers of alcoholic beverages. Currently there are no approved treatments for AL
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
5. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
8. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
9. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015 The treatment pipeline for ... says  GBI Research . ... Acute Myeloid Leukemia Therapeutics Market to 2020 - forecasts ... moderately from $632.6 million in 2013 to $878.6 million by ... Several drugs to treat AML are expected to ...
(Date:6/3/2015)... SHANGHAI , June 3, 2015 MEDTEC China South ... an extension of MEDTEC China 2015, MEDTEC China South has ... attributes, standing out as a key event for the medical ... After many years of challenges, this year marks the successful return ... 10 years after the event first debuted there in 2005. ...
(Date:6/3/2015)... 2015  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... opioid overdose with intranasal naloxone, has commenced a ... to the United States Food and Drug Administration ... a drug intended to treat opioid overdose.  A ...
Breaking Medicine Technology:Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 2Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 3MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... MUNDELEIN, Ill. , July 20 ... and information systems technology, today announced the addition of ... Sysmex hematology product offering.  The DM1200 enables Sysmex America ... analysis, which improves both the quality of results and ...
... Mich. , July 20 Two southeast Michigan ... in the region.  Delphinus Medical Technologies and Quantum Signal were approved today for ... of Michigan . , , , ... Arbor region continues to be a magnet for growing, high tech companies," ...
Cached Medicine Technology:Sysmex America Begins Distribution of CellaVision® DM1200 2Sysmex America Begins Distribution of CellaVision® DM1200 3Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area 2Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area 3
(Date:6/3/2015)... On Sunday, June 7, 2015, tens of ... their local communities to observe the 28th annual National ... and abroad will hold celebrations on this day to ... challenges of cancer survivorship, and to show the world ... rewarding, and inspiring.,  , National Cancer Survivors Day® is ...
(Date:6/3/2015)... are challenging and unpredictable times for traditional organizations across ... are rewriting the rules for business as we knew ... businesses to take on a more agile approach in ... On top of this there is a growing trend ... new innovation and approaches to business. , The manager ...
(Date:6/3/2015)... ON (PRWEB) June 03, 2015 On ... a Marketing Authorization (MA), effective immediately, which now permits ... foods that contain oats as ingredients. The MA is ... being developed. All stakeholders should be aware that, unlike ... in the USA, there are restrictions for gluten-free oat ...
(Date:6/3/2015)... Veatch Consulting Services is excited to ... opened for business in April 2006, they have made ... their clients. Each and every year they have worked ... proud to say that they are off to a ... recently added this year is the Customer Review site ...
(Date:6/2/2015)... BALTIMORE, Md. – Ellarea Maria ... about wellness after being diagnosed with lupus. In spite ... lifestyle changes which enhance health, lupus and other autoimmune ... Wellspring for Wellness ,” she offers a holistic approach ... book provides an overview of some autoimmune diseases—especially ...
Breaking Medicine News(10 mins):Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 3Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3
... By Amanda Gardner HealthDay Reporter , THURSDAY, March ... that screening for prostate cancer does not substantially reduce the ... hand, a good many men might receive false-positive results and ... researchers report in the March 31 online issue of the ...
... A potential new experimental diagnostic test able to quickly ... latent TB infection has been developed. If the preliminary ... larger population sample, the new diagnostic system could allow ... re-emerging pathology. The work was performed by ...
... system to perform in vivo RNAi screens for ... hepatocyte proliferation during chronic liver damage.1 Functional ... of the candidate gene by different shRNAs can ... and also increase the regenerative capacity of chronically ...
... new TNM 7 lung cancer staging system seems to ... of lung cancer following surgery, according to a study ... of Thoracic Oncology . Being able to better ... important, especially given the controversies surrounding the use of ...
... target for lung cancer has been discovered by researchers at ... the protein AIMP2 is highly expressed in lung cancer cells ... show lower survival. The study is published on March 31 ... Lung cancer is one of the world,s most common cancers ...
... leading cancer organizations shows rates of death in the United States ... 2003 and 2007. The findings come from the latest Annual Report ... report also finds that the overall rate of new cancer diagnoses ... than 1 percent per year for the same period. Edward ...
Cached Medicine News:Health News:Prostate Cancer Screening Doesn't Cut Death Rates: Study 2Health News:Prostate Cancer Screening Doesn't Cut Death Rates: Study 3Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 2Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 3
... With the GE Innova 2100IQ: See the ... legs. Place interventional devices. Its all enabled ... panel that helps deliver excellent image quality ... Innova family systems installed worldwide, more physicians ...
... provides clinically valuable, device-derived information applicable ... to help specialty physicians discern if ... stable or deteriorating. For example, heart ... Medtronic InSync Sentry™ CRT-D system can ...
... (ALS) is a GH dependent protein which is ... acid peptide with a predicted molecular weight of ... confined to a ~150 KDa GH-dependent ternary protein ... or IGF-II, and this unique acid-labile subunit (ALS) ...
... was first identified in 1980 (1) and has ... of appetite (2). PYY is produced by the ... intake, and is found to decrease appetite. The ... the circulation is PYY3-36, the N-terminal truncated form ...
Medicine Products: